Immediate vs bridging transplant for high-risk MDS
Part of Blood & lymphatic clinical trials.
This trial compares getting a stem cell transplant right away versus getting other treatments first before transplant for people with high-risk myelodysplastic syndrome (MDS), a bone marrow disorder. It aims to see which approach leads to better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have high-risk MDS based on specific scoring systems (IPSS-R or IPSS-M).
- You are healthy enough for a stem cell transplant (able to do most daily activities, with a performance score of 60 or higher).
- You have a donor available (related or unrelated, even if not perfectly matched).
- Your major organs (heart, lungs, liver, kidneys) work well enough for transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at using a family donor transplant right away for people with higher-risk myelodysplastic syndrome (MDS). The goal is to see if this early transplant is safe and helps control the disease.
This trial tests a stem cell transplant that uses specially selected cells (CD34+ cells) to treat myelodysplastic syndrome (MDS), a blood disorder. The transplant comes from a donor and aims to replace unhealthy blood-forming cells with healthy ones, which may slow or stop the disease. It is designed for patients with higher-risk MDS or certain high-risk features.
This trial tests a conditioning regimen that is adjusted by age for people with low- or intermediate-risk myelodysplastic syndromes (MDS) who are receiving a half-matched (haploidentical) stem cell transplant from a family donor. The goal is to see if an age-stratified approach can improve outcomes.
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
This trial tests a less intense chemotherapy and radiation combination (called TMLI, fludarabine, and melphalan) before a stem cell transplant from a matched donor. The goal is to help prepare your body for the transplant while reducing side effects, so it may be a good option if you have high-risk MDS or AML and cannot tolerate the standard, more intensive conditioning regimen.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.